Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Two-arm, Parallel-Group, Single-dose Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects

NCT07200986 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.

NCT NCT07200986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07200986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Two-arm, Parallel-Group, Single-dose Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects
Lead sponsor
Celltrion
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 17, 2025
Completion date
March 31, 2026
Enrollment
218 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants